Publications
Explore a selection of our publications to date below.
| Image | Title | Year | journal_hfilter | paper_type_hfilter | focus_hfilter | test_hfilter | tumor_type_hfilter | biomarker_hfilter | publication_year_hfilter |
|---|---|---|---|---|---|---|---|---|---|
 | Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay | 2019 | oncotraget | manuscript | analytical | msi | solid-tumors | analytical-validation | 2019 |
 | Unique Tumor Immune Microenvironments Of Potentially PD-L1/TGF-β Trap Responsive Tumors | 2019 | sitcs-34th-annual-meeting-2019 | abstract | clinical | irc | solid-tumors | bispecifics tumor-immune-microenvironment | 2019 |
| CT Antigens are Frequently Expressed in Non-Inflamed Tumors | 2019 | sitcs-34th-annual-meeting-2019 | abstract | clinical | irc | solid-tumors | ct-antgiens tumor-immune-microenvironment | 2019 |
 | Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing | 2019 | journal-of-immunotherapy-and-precision-oncology | manuscript | analytical | tcrb | peripheral-blood-leukocytes | haplotype-analysis | 2019 |
 | Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC | 2019 | journal-of-thoracic-oncology | manuscript | clinical | oirra | solid-tumors | bmi immune-profile metformin | 2019 |
| Oncologist uptake of comprehensive genomic profile guided targeted therapy | 2019 | oncotraget | manuscript | clinical | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
 | Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | abstract | clinical | irc | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
| Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC) | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | abstract | clinical | irc | renal-cell-carcinoma | cell-proliferation patient-response tumor-inflammation | 2019 |
| Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | abstract | analytical | tmb | solid-tumors | comparator-study specimen-characteristics validation | 2019 |
| RNA-sequencing reveals immunotherapy targets in gynecological cancer | 2019 | asco-sitc-clinical-immuno-oncology-symposium-2019 | abstract | clinical | irc | gynocological-cancers | immune-profile immune-suppression | 2019 |
 | Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients | 2019 | journal-for-immunotherapy-of-cancer | manuscript | clinical | irc | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2019 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors | 2019 | journal-for-immunotherapy-of-cancer | manuscript | analytical | pd-l1-ihc pd-l1-rna-seq | solid-tumors | comparator-study patient-response pd-l1 | 2019 |
| Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing | 2019 | bmc-medical-informatics-and-decision-making | manuscript | clinical | ocp | solid-tumors | clinical-decision-making clinical-utility | 2019 |
 | RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma | 2018 | journal-of-sarcoma-research | manuscript | clinical | irc | sarcoma | immune-profile myeloid-suppression | 2018 |
 | Identification of targets for prostate cancer immunotherapy | 2018 | the-prostate | manuscript | clinical | irc | prostate-cancer | immune-profile | 2018 |
 | Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platforms | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | analytical | tmb | solid-tumors | comparator-study tmb | 2018 |
| Identifying major immune subsets of GI tumors for clinical purposes | 2018 | sitcs-33rd-annual-meeting-2018 | abstract | clinical | irc | gi-tumors | immune-profile | 2018 |
| Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing | 2018 | sitcs-33rd-annual-meeting-2018 | abstract | analytical | msi | solid-tumors | analytical-validation | 2018 |
| Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | clinical | pd-l1-22c3 | non-small-cell-lung-cancer | cell-proliferation patient-survival | 2018 |
 | Combination immunotherapy selection for non-PD-1 axis driven tumors | 2018 | 2018-asco-annual-meeting | abstract | clinical | oirra | solid-tumors | immune-profile | 2018 |
| Combination immunotherapy selection for PD-1 axis driven tumors | 2018 | 2018-asco-annual-meeting | abstract | clinical | oirra | solid-tumors | immune-profile | 2018 |
 | PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab | 2018 | oncoimmunology | manuscript | clinical | irc | urothelial-carcinoma | immune-profile patient-response pd-l2 | 2018 |
 | Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden | 2018 | journal-for-immunotherapy-of-cancer | manuscript | clinical | irc | melanoma | patient-survival tumor-inflammation | 2018 |
 | Chemokine expression signatures in infiltrated vs non-infiltrated tumors | 2018 | aacr-annual-meeting-2018 | abstract | clinical | irc | solid-tumors | chemokines infiltrated-tumors tumor-infiltrating-lymphocytes | 2018 |
| PD-L1 driven excluded phenotype in melanoma | 2018 | aacr-annual-meeting-2018 | abstract | clinical | irc | melanoma | cd8 excluded-phenotype | 2018 |
| Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq | 2018 | aacr-annual-meeting-2018 | abstract | analytical | irc | solid-tumors | patient-response pd-l1 | 2018 |
 | Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | clinical | irc | solid-tumors | cd8 patient-response | 2018 |
| Comprehensive Immune and Mutational Profile of Melanoma | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | clinical | oa | melanoma | immune-profile mutational-profile | 2018 |
| CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | clinical | oa | melanoma | ctla4 patient-response | 2018 |
| Lung Cancer Mutational Profile Correlates with Immune Profile | 2018 | asco-sitc-clinical-immuno-oncology-symposium-2018 | abstract | clinical | irc | lung-cancer | immune-profile mutational-profile | 2018 |
 | Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype | 2017 | sitcs-32nd-annual-meeting-2017 | abstract | clinical | irc | solid-tumors | immune-desert immune-profile | 2017 |
| Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠ | 2017 | sitcs-32nd-annual-meeting-2017 | abstract | clinical | irc | solid-tumors | immune-profile | 2017 |
| The Immune-Excluded Phenotype Beyond Colorectal Cancer | 2017 | sitcs-32nd-annual-meeting-2017 | abstract | clinical | irc | solid-tumors | cd8 excluded-phenotype | 2017 |
| Secondary Immunotherapeutic Targets In Inflamed Tumors | 2017 | sitcs-32nd-annual-meeting-2017 | abstract | clinical | irc | solid-tumors | immune-profile tumor-inflammation | 2017 |
 | Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors | 2017 | the-journal-of-molecular-diagnostics | manuscript | analytical | irc | solid-tumors | analytical-validation | 2017 |
 | Algorithmic Prediction of Response to Checkpoint Inhibitors | 2017 | 2017-asco-annual-meeting | abstract | analytical | oirra | solid-tumors | patient-response predicitve-algorithm | 2017 |
 | The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors | 2017 | immunology-2017 | abstract | clinical | irc | melanoma | patient-response tumor-inflammation | 2017 |
| The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors | 2017 | immunology-2017 | abstract | clinical | irc | non-small-cell-lung-cancer | patient-response tumor-inflammation | 2017 |
 | Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification | 2017 | aacr-annual-meeting-2017 | abstract | analytical | irc | solid-tumors | specimen-characteristics validation | 2017 |
| NGS reveals specimen characteristics have minimal impact on immune gene expression signature | 2017 | aacr-annual-meeting-2017 | abstract | analytical | oirra | specimen-characteristics validation | 2017 | |
| Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient | 2017 | aacr-annual-meeting-2017 | abstract | analytical | irc | solid-tumors | specimen-characteristics validation | 2017 |
 | Analytical Validation of an Immune Response Assay for Classifying Solid Tumors | 2017 | 2017-asco-annual-meeting | abstract | analytical | irc | analytical-validation | 2017 | |
| Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing | 2016 | oncotraget | manuscript | analytical | irc | solid-tumors | comparator-study specimen-characteristics validation | 2016 |
 | An Algorithmic Approach to Cancer Immune Profiling | 2016 | sitcs-31st-annual-meeting-2016 | abstract | analytical | irc | solid-tumors | patient-response predicitve-algorithm | 2016 |
| Validation of a Custom RNA-Seq Approach to Cancer Immune Profiling | 2016 | sitcs-31st-annual-meeting-2016 | abstract | analytical | irc | solid-tumors | comparator-study specimen-characteristics validation | 2016 |